Ruffer Portfolio holdings
Ruffer is an independent investment manager owned and run by its partners, with a single global strategy aimed at not losing money over any rolling 12-month period. Jonathan Ruffer, who began as a stockbroker and then became a barrister, started it in 1994 with Robert Shirley, 14th Earl Ferrers, and Jane Tufnell, and it became Ruffer LLP in 2004. The firm starts by weighing the risks it sees in markets and picking assets that should protect the portfolio if they come true, then takes on growth mainly through global stocks. It runs a stock-market-listed investment company, and its clients include pension plans, charities and family offices.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$115M |
| 2 |
Cigna
CI
|
+$76.9M |
| 3 |
Wheaton Precious Metals
WPM
|
+$42.8M |
| 4 |
Avis
CAR
|
+$40.3M |
| 5 |
Kinross Gold
KGC
|
+$36.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$183M |
| 2 |
Centene
CNC
|
+$137M |
| 3 |
American Express
AXP
|
+$42.7M |
| 4 |
Nutrien
NTR
|
+$38.8M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$19.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.32% |
| 2 | Materials | 22.81% |
| 3 | Financials | 15.4% |
| 4 | Consumer Staples | 10.93% |
| 5 | Energy | 10% |
Similar funds
Ruffer's Q3 2021 Portfolio in Review
As of Q3 2021, Ruffer held 98 positions worth $3.16B, down 11% from $3.57B the previous quarter. Its ten largest holdings account for 64% of the portfolio.
Ruffer's Q3 2021 filing shows 9 new, 25 increased, 29 reduced and 8 closed positions. Its largest new stake was AstraZeneca: 985,898 shares worth $117M. The largest sale was Alexion Pharmaceuticals, an estimated $183M.
By sector, the portfolio is most concentrated in Healthcare at 31% of assets, down from 35% a quarter earlier, followed by Materials and Financials.
- Ruffer's largest Q3 2021 buy was AstraZeneca: 985,898 shares worth $117M.
- Ruffer added most to Cigna in Q3 2021, an estimated $76.9M increase.
- Ruffer's biggest Q3 2021 reduction was Centene, cutting an estimated $137M.
- Ruffer fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $183M.
- Ruffer's ten largest holdings make up 64% of its $3.16B portfolio in Q3 2021.
- Ruffer opened 9 new positions and closed 8 in Q3 2021.
- Ruffer's portfolio value fell 11% quarter-over-quarter to $3.16B.
Based on Ruffer's 13F filing for Q3 2021, filed 10 Nov 2021.